Fulvestrant

SEP 9, 2026 · PHASE 1 TRIAL

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

ClinicalTrials.gov

This is a Phase 1, first-in-human study registration with no results posted; it describes planned enrollment and safety endpoints only, representing early-stage drug development.

SEP 8, 2026 · PHASE 1 TRIAL

A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors

ClinicalTrials.gov

Phase 1 trial registration with no posted results; study is actively recruiting and designed to establish safety and tolerability rather than efficacy.

SEP 8, 2026 · PHASE 1 TRIAL

To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer

ClinicalTrials.gov

This is a Phase 1 safety and pharmacokinetics study registration with no results posted; it describes planned enrollment and design only, typical of early-stage clinical development.

SEP 4, 2026 · PHASE 2 TRIAL

To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer

ClinicalTrials.gov

This is a Phase 2 interventional trial currently recruiting; no results are posted in this registry record, making it an early-stage study with unknown efficacy and safety outcomes.

SEP 4, 2026 · PHASE 1 TRIAL

Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer

ClinicalTrials.gov

This is a Phase 1 safety and tolerability study in early recruitment with no results posted; it is designed to evaluate dose-limiting toxicities and adverse events, not efficacy.

SEP 4, 2026 · PHASE 1/2 TRIAL

Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

ClinicalTrials.gov

This is a clinical trial registry record describing a planned Phase 1b/2 study with no results reported; it documents the protocol and design only.

AUG 20, 2026 · PHASE 2 TRIAL

Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors

ClinicalTrials.gov

This is a Phase 1/2A open-label, non-randomized safety and tolerability study of an investigational agent; no results are reported in this registry record.

AUG 20, 2026 · PHASE 1 TRIAL

[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer

ClinicalTrials.gov

Phase 1 dose-escalation study with safety endpoints only; no efficacy results reported in registry record. Designed to establish recommended dose of [177Lu]Lu-NeoB in combination therapy.